drugset / Trial / NCT07397468
To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a double-blind, placebo-controlled, randomized study of 96 days total duration to assess the effect of JUV-161 on muscle disuse atrophy. This will be a multicenter study in New Zealand and will include up to 40 healthy volunteers aged between 40 to 65 years of age. Following the screening period, subjects will be randomized to receive either weekly subcutaneous (SC) injections of one of two doses of JUV-161 or matching placebo for a period of approximately 6 weeks.
Timeline
- Start
- 2026-02-28
- Primary completion
- 2026-07-31
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JUV-161 | Unknown | 5 mg/kg | Subcutaneous |
| Subject | JUV-161 | Unknown | 10 mg/kg | Subcutaneous |
Indications
No indication recorded.